openPR Logo
Press release

Endometriosis Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2024-2034), Analyzes DelveInsight | Enteris BioPharma, Spago Nanomedical, Iqvia Pty, Myovant Sciences, others

04-25-2024 04:24 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Endometriosis Market is Predicted to Exhibit Remarkable Growth

The Endometriosis Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Endometriosis, historical and forecasted epidemiology as well as the Endometriosis market trends in the 7MM.
DelveInsight's "Endometriosis Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Endometriosis, historical and forecasted epidemiology as well as the Endometriosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Endometriosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Endometriosis Market Forecast [https://www.delveinsight.com/sample-request/endometriosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Endometriosis Market Report:

*
The Endometriosis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In November 2023, Gedeon Richter and Sumitomo Pharma jointly revealed that the European Commission had approved a Type II Variation application for RYEQO (consisting of relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg). This approval pertains to the symptomatic treatment of endometriosis in women who have undergone previous medical or surgical interventions for their condition.

*
According to information from the World Health Organization (2023), approximately 10% of reproductive-age women and girls worldwide, totaling around 190 million individuals, are impacted by endometriosis.

*
In 2023, the estimated number of diagnosed prevalent cases of endometriosis in the US stood at approximately 4,800,000 cases, with a potential increase anticipated by 2034.

*
In 2023, it was noted that the largest population of individuals affected by endometriosis in the US fell within the 18-29 age bracket, with approximately 5,000,000 cases.

*
In 2023, the diagnosed prevalent cases of endometriosis categorized by pain severity in the US were approximately 1,200,000 for mild, 1,900,000 for moderate, and 1,600,000 for severe. These figures are projected to increase during our forecast period from 2024 to 2034.

*
Key Endometriosis Companies: Enteris BioPharma Inc., Spago Nanomedical AB, Iqvia Pty Ltd, Nanjing Chia-tai Tianqing Pharmaceutical, Myovant Sciences GmbH, Hope Medicine (Nanjing) Co., Ltd, Ferring Pharmaceuticals, Jiangsu HengRui Medicine, ObsEva, AbbVie, ASKA Pharmaceutical Co., Ltd., Abbott, Kissei Pharmaceutical Co., Ltd., Bayer, Pfizer, and others

*
Key Endometriosis Therapies: Leuprolide Oral Tablet, SN132D, OG-6219, Elagolix, Relugolix, HMI-115, Quinagolide 1080 g, OBE2109, SASHR7280, Estradiol/Norethindrone Acetate, TAK-385, NBI-56418 (GnRH antagonist), KLH-2109, Dienogest (Visanne, BAY86-5258), ERB-041, and others

*
As per the findings of Yoshino et al. (2022), around 2.6 million women in Japan are impacted by endometriosis.

*
The Endometriosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Endometriosis pipeline products will significantly revolutionize the Endometriosis market dynamics.

Endometriosis Overview

Endometriosis is a chronic condition where tissue similar to the lining of the uterus grows outside the uterus. This tissue behaves like uterine lining, thickening and bleeding during the menstrual cycle. However, as it's displaced, it becomes trapped, leading to pain, inflammation, and sometimes fertility issues.

Get a Free sample for the Endometriosis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/endometriosis-market [https://www.delveinsight.com/report-store/endometriosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Endometriosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Endometriosis Epidemiology Segmentation:

The Endometriosis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Endometriosis

*
Prevalent Cases of Endometriosis by severity

*
Gender-specific Prevalence of Endometriosis

*
Diagnosed Cases of Episodic and Chronic Endometriosis

Download the report to understand which factors are driving Endometriosis epidemiology trends @ Endometriosis Epidemiology Forecast [https://www.delveinsight.com/sample-request/endometriosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Endometriosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Endometriosis market or expected to get launched during the study period. The analysis covers Endometriosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Endometriosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Endometriosis Therapies and Key Companies

*
Leuprolide Oral Tablet: Enteris BioPharma Inc.

*
SN132D: Spago Nanomedical AB

*
OG-6219: Iqvia Pty Ltd

*
Elagolix: Nanjing Chia-tai Tianqing Pharmaceutical

*
Relugolix: Myovant Sciences GmbH

*
HMI-115: Hope Medicine (Nanjing) Co., Ltd

*
Quinagolide 1080 g: Ferring Pharmaceuticals

*
OBE2109: ObsEva

*
SASHR7280: Jiangsu HengRui Medicine

*
Estradiol/Norethindrone Acetate: AbbVie

*
TAK-385: ASKA Pharmaceutical Co., Ltd.

*
NBI-56418 (GnRH antagonist): Abbott

*
KLH-2109: Kissei Pharmaceutical Co., Ltd.

*
Dienogest (Visanne, BAY86-5258): Bayer

*
ERB-041: Pfizer

Discover more about therapies set to grab major Endometriosis market share @ Endometriosis Treatment Landscape [https://www.delveinsight.com/sample-request/endometriosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Endometriosis Market Strengths

*
The rising prevalence of endometriosis is the primary strength of its global market, leading to more focus by pharmaceutical firms

*
At national and international levels, government and key market players actively invest in research and development and increase funds, further catering to market growth.

Endometriosis Market Opportunities

*
Incumbents are paired with healthcare providers to raise awareness in the field of endometriosis at the physician and patient levels

*
New diagnostic tools and techniques or methods can be explored for the early detection of endometriosis in the affected patient pool

Scope of the Endometriosis Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Endometriosis Companies: Enteris BioPharma Inc., Spago Nanomedical AB, Iqvia Pty Ltd, Nanjing Chia-tai Tianqing Pharmaceutical, Myovant Sciences GmbH, Hope Medicine (Nanjing) Co., Ltd, Ferring Pharmaceuticals, Jiangsu HengRui Medicine, ObsEva, AbbVie, ASKA Pharmaceutical Co., Ltd., Abbott, Kissei Pharmaceutical Co., Ltd., Bayer, Pfizer, and others

*
Key Endometriosis Therapies: Leuprolide Oral Tablet, SN132D, OG-6219, Elagolix, Relugolix, HMI-115, Quinagolide 1080 g, OBE2109, SASHR7280, Estradiol/Norethindrone Acetate, TAK-385, NBI-56418 (GnRH antagonist), KLH-2109, Dienogest (Visanne, BAY86-5258), ERB-041, and others

*
Endometriosis Therapeutic Assessment: Endometriosis current marketed and Endometriosis emerging therapies

*
Endometriosis Market Dynamics: Endometriosis market drivers and Endometriosis market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Endometriosis Unmet Needs, KOL's views, Analyst's views, Endometriosis Market Access and Reimbursement

To know more about Endometriosis companies working in the treatment market, visit @ Endometriosis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/endometriosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Endometriosis Market Report Introduction

2. Executive Summary for Endometriosis

3. SWOT analysis of Endometriosis

4. Endometriosis Patient Share (%) Overview at a Glance

5. Endometriosis Market Overview at a Glance

6. Endometriosis Disease Background and Overview

7. Endometriosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Endometriosis

9. Endometriosis Current Treatment and Medical Practices

10. Endometriosis Unmet Needs

11. Endometriosis Emerging Therapies

12. Endometriosis Market Outlook

13. Country-Wise Endometriosis Market Analysis (2020-2034)

14. Endometriosis Market Access and Reimbursement of Therapies

15. Endometriosis Market Drivers

16. Endometriosis Market Barriers

17. Endometriosis Appendix

18. Endometriosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=endometriosis-market-is-predicted-to-exhibit-remarkable-growth-during-the-forecast-period-20242034-analyzes-delveinsight-enteris-biopharma-spago-nanomedical-iqvia-pty-myovant-sciences-others]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Endometriosis Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2024-2034), Analyzes DelveInsight | Enteris BioPharma, Spago Nanomedical, Iqvia Pty, Myovant Sciences, others here

News-ID: 3476743 • Views:

More Releases from ABNewswire

Northwest Exteriors Urges Homeowners to Replace Windows Before Winter Weather Arrives
Northwest Exteriors Urges Homeowners to Replace Windows Before Winter Weather Ar …
Rancho Cordova, CA - December 1, 2025 - With colder temperatures quickly approaching, Northwest Exteriors is encouraging homeowners across California and Hawaii to take proactive steps in preparing their homes by investing in energy-efficient replacement windows. Known for their expert craftsmanship and commitment to energy savings, Northwest Exteriors helps residents stay warm, reduce utility costs, and eliminate drafts before winter sets in. Replacing outdated or damaged windows before winter not only
Chief Businessaire Ja'von L. Watson Announces Groundbreaking Business Book: Unfamiliar But Chartered Territory For Every Beginner
Chief Businessaire Ja'von L. Watson Announces Groundbreaking Business Book: Unfa …
Visionary entrepreneur, author, economic innovator, and tech founder Chief Businessaire Ja'von L. Watson unveils his highly anticipated business book, Unfamiliar But Chartered Territory, a transformative roadmap designed to empower emerging entrepreneurs, business leaders, and ambitious innovators navigating the unknown terrain of today's marketplace. The book defines what is at risk when you pursue entrepreneurship. In a business climate defined by disruption, reinvention, and bold risk-taking, Unfamiliar But Chartered Territory introduces a
EDsmart Analysis Reveals the 50 Safest Jobs in Today's AI Economy
EDsmart Analysis Reveals the 50 Safest Jobs in Today's AI Economy
EDsmart's new analysis of 784 U.S. occupations identifies the 50 jobs least vulnerable to automation in today's AI economy. These roles--centered in construction, production, and skilled trades--show 0.0% AI exposure in the Wharton Budget Model, making them the safest career paths for long-term stability. The report offers insights for workers, students, and policymakers navigating rapid AI-driven change. As AI reshapes the U.S. workforce at unprecedented speed, a new EDsmart report identifies
SunBelt Home Sales Encourages Buyers and Sellers to Act Now Before 2026 Market Shifts
SunBelt Home Sales Encourages Buyers and Sellers to Act Now Before 2026 Market S …
As the year draws to a close, SunBelt Home Sales, Central Florida's trusted agency for manufactured home buying and selling, is advising buyers and sellers to take advantage of current market conditions before changes expected in early 2026. With a steady stream of incoming Florida residents and evolving economic factors on the horizon, December is a prime time to make a move. Orlando, FL - December 1, 2025 - As the

All 5 Releases


More Releases for Endometriosis

Endometriosis Treatment Market at $1.55B, 7.7% CAGR
Why Is the Global Endometriosis Treatment Market Expanding So Quickly? The endometriosis treatment market has grown rapidly in recent years, primarily due to increased awareness, better diagnostic technologies, rising cases of reproductive health disorders, and significant investment in research and drug development. With the market valued at USD 1.55 billion in 2024 and expected to reach USD 3.25 billion by 2034, the global demand for effective treatments continues to accelerate. Endometriosis affects
Endometriosis Pain Market Massive Growth opportunity Ahead
Introduction Endometriosis is a chronic, estrogen-dependent condition in which endometrial-like tissue grows outside the uterus, leading to inflammation, scarring, and adhesions. One of its most debilitating symptoms is pelvic pain, often accompanied by painful periods, infertility, and fatigue. Globally, endometriosis affects an estimated 10% of women of reproductive age, making it a major public health concern. Despite its prevalence, endometriosis pain has historically been underdiagnosed and undertreated. Patients often face diagnostic delays
Elevated Ovarian Cancer Incidence Fuels Growth In The Endometriosis Market: A Ke …
The Endometriosis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Current Endometriosis Market Size and Its Estimated Growth Rate? In recent years, there has been a swift expansion in the market size of endometriosis. This market is projected to increase from $1.4 billion
Hope for Rapid, Non-Invasive Endometriosis Diagnosis
New diagnostic test for endometriosis, the ENDOSURE test, offers decision support to clinicians with 99.87% accurate results in less than an hour, could transform women's healthcare EDMONTON, AB - In a groundbreaking development for women's health featured on Global News Calgary by journalist Jayme Doll on March 12, 2025, the ENDOSURE test emerges as a beacon of hope for millions suffering from undiagnosed endometriosis in. This non-invasive diagnostic tool promises to
Emerging Endometriosis Market Trend 2025-2034: Innovative Medications Reshaping …
"How Is the Endometriosis Market Projected to Grow, and What Is Its Market Size? The endometriosis market has seen rapid growth in recent years. It is expected to grow from $1.4 billion in 2024 to $1.55 billion in 2025, at a compound annual growth rate (CAGR) of 10.2%. The growth can be attributed to delayed diagnosis, increased awareness, advances in laparoscopic surgery, hormonal therapies, and the support of patient advocacy groups. The
Endometriosis Treatment Market Analysis, Size, Share & Trends | 2031
In recent years, the global Endometriosis Treatment Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Endometriosis Treatment Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including Porters Five